Zymvol, a Barcelona-based biotech firm specializing in enzyme search and engineering, has raised €3M in seed funding led by Faber Ventures. The funding will be utilized to enhance its Barcelona Science Park lab, improve technology, and grow its sales team. Zymvol aims to scale its operations in Europe and North America, particularly in the pharmaceutical sector. By utilizing computational methods, the company seeks to democratize enzyme development, making it more efficient and cost-effective compared to traditional trial-and-error approaches, thus driving sustainable innovation across various industries.
Enzymes power innovation across industries, from sustainable manufacturing to pharmaceutical breakthroughs. Zymvol's advanced computational solutions improve efficiency and strengthen industrial resilience.
Our plans include growing our presence in the European and North American market, as well as expanding our business with Pharma, and Generics companies.
Collection
[
|
...
]